Transgene will pick up an up-front payment of $17.4 million in a new collaboration pact with Roche covering TG 4001, a vaccine candidate for pre-cancerous cervical abnormalities. Another $13 million milestone is payable on certain conditions related to Phase III planning and $261.5 million in milestones are scheduled for sales and regulatory milestones. Roche gains the right to worldwide development and marketing.
"We are delighted by Roche's commitment to further develop our promising vaccine TG 4001 in the field of HPV-mediated diseases,' said Philippe Archinard, CEO of Transgene. "Roche has broad expertise and a leadership position in the development and marketing of first-in-class innovative therapies. This first strategic partnership is an acknowledgment of the validity of our technology and strategy. It is a considerable transforming event for Transgene that we anticipate will enable us to accelerate and broaden the development of our entire product portfolio."
- see this release on the deal
- got to this International Herald Tribune report for more